U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07475052) titled 'Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD' on Dec. 25, 2025.
Brief Summary: This is a prospective, multicenter, observational cohort study, which plans to enroll patients with active IBD who are scheduled to initiate IFX or VDZ treatment between October 2025 and October 2027 at Xijing Hospital, Tang-du Hospital, and Air Force 986 Hospital. All patients will undergo HRV monitoring at baseline, Week 2, Week 6, and Week 14. The HRV monitoring results will be blinded to both physicians and patients. Based on the efficacy assessment at Week 14, patients will be divided into response and non-response gr...